CARM | Carisma Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.4053 - 0.4414
52 Week Range	0.3810 - 3.16
Beta	2.57
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	302,641
Average Volume	209,639
Shares Outstanding	41,750,100
Market Cap	17,447,367
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-02-06

Valuation
Profitability
Growth
Health
P/E Ratio	-0.27
Forward P/E Ratio	N/A
EPS	-1.52
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	107
Country	USA
Website	CARM

Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.

CARM's peers: CNSP, ZVSA, EFTR, VECT, AVRO, IMMX, HEPA, SRNEQ, ZURA, CYTO, ENVB, PALI

*Chart delayed

Analyzing fundamentals for CARM we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see CARM Fundamentals page.

Watching at CARM technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CARM Technicals page.